Approaches such as machine learning, AI and neural networks are still in their infancy, but with AI companies rewriting the code for drug discovery, the implications in pharma are likely to be far ranging in the coming years.
Pablo Lubroth
Advertisement
Articles by Pablo Lubroth
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Clinical Trials: What the FDA's Push Toward Continuous Oversight Means for Sponsors
2
ACT Brief: DIA Leadership and Infrastructure Priorities, Real-Time Data Review Readiness, and CLL Treatment Expansion
3
Built-In, Not Bolted On: Why Clinical Data Security Has to Be a Design Principle
4
ACT Brief: Bridging Site-Sponsor Data Gaps, Major Study Retraction, and TNBC First-Line Approval
5